The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

Article January 1, 1999

Consensus Discussion: Pharmacoeconomics of Treatment-Resistant Schizophrenia

J Clin Psychiatry 1999;60(suppl 1):28-30

Article Abstract

Consensus Discussion

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Article

Psychotropic Medication Monitoring

February 21, 2019

Psychotropic medications provide therapeutic benefits but also carry iatrogenic risks. Medication monitoring helps minimize this risk. This CME journal article offers clinicians a review of guidelines and presents monitoring...

Matthew A. Schreiber , Stephanie C. Armstrong , Jesse D. Markman

Article

Acute Blood Pressure Changes With Antipsychotic Use

July 19, 2018

Could administration of certain antipsychotic medications be associated with significant acute blood pressure changes? The authors of this study attempted to answer this question by investigating blood pressure changes...

Kristin A. Parks , Clayton G. Parks , Johnathon P. Yost , et al

Article

Adherence to Follow-Up in First-Episode Psychosis: Ethnicity Factors

June 7, 2018

Do visible minority patients have poorer service engagement and follow-up in mental health care in Canada? The objective of this study was to determine whether visible minority patients with...

Katerina Nikolitch , Andrew Ryder , G. Eric Jarvis

Consensus Discussion: Pharmacoeconomics of Treatment-Resistant Schizophrenia

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

ELSEWHERE:

FOLLOW US:

Consensus Discussion: Pharmacoeconomics of Treatment-Resistant Schizophrenia

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

Related Articles

Psychotropic Medication Monitoring

Acute Blood Pressure Changes With Antipsychotic Use

Adherence to Follow-Up in First-Episode Psychosis: Ethnicity Factors

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles